Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

From Friends To Foes: Tekmira Slaps Partner Alnylam With Lawsuit

This article was originally published in The Pink Sheet Daily

Executive Summary

Suit alleges Alnylam stole Tekmira's RNAi delivery technology, but Alnylam dismisses the claims and says its delivery technology falls within its licensing agreement or other partnerships.

You may also be interested in...



Does Alnylam Lift All Oligo Boats? The Dicerna IPO

Dicerna’s debut stood out even in a hot market for biotech IPOs, but it is hard to sort out how much investor enthusiasm was driven by its specific technologies, rub-off from the recent Alnylam/ Sanofi-Genzyme deal, and demands of insiders who wanted liquidity but not dilution.

Alnylam Sheds Legal Trouble But Picks Up Manufacturing Challenge In Tekmira Settlement

Alnylam is paying Tekmira $65 million to resolve an RNAi trade secrets suit; the new licensing pact reduces Alnylam’s future milestone and royalty payments on three compounds and allows the firm to manufacture its own drug candidates.

The Alnylam Turnaround: What Changed Investors’ Minds?

Alnylam’s release of early-stage clinical data for its lead amyloidosis project in July caused a surge in its market value and rare cheers from investors. Years removed from its most recent high-profile technology deal, Alnylam is a company on the verge of completing the trickiest metamorphosis in biotech: from technology platform to product focus without the benefit of transformational M&A.

Related Content

Topics

UsernamePublicRestriction

Register

ID1129947

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel